Ahead of ASCO: is mezigdomide still being framed too conservatively?

Ahead of BMY’s SUCCESSOR-2 late-breaker at ASCO next weekend, our mezigdomide report examins whether the market is still too conservative on its clinical and commercial relevance in post-lenalidomide relapse. Our focus is less on whether the programme has activity at all, and more on whether the current framing understates its potential to drive a more meaningful backbone reset if Phase III superiority and commercial uptake prove sufficient.

Our latest BMY report addresses three key investor questions:

·       Is mezigdomide best framed as a replacement story rather than a narrower franchise-defence story?

·       Which of the pivotal programmes matters more for the investment case?

·       What level of adoption would make mezigdomide merely defensive versus genuinely value-accretive?